Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2022-02-28 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE FIRST PATIENT DOSED IN THE PHASE IIA STUDY OF CLAUDIN18.2 MONOCLONAL ANTIBODY TST001 COMBINED WITH CISPLATIN AND GEMCITABINE FOR THE FIRST LINE TREATMENT
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Transcenta Holding Limited providing a business update on the dosing of the first patient in a Phase IIa clinical study for a monoclonal antibody treatment. It is an announcement about a clinical trial progress and business update rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, audit information, or governance details. It is not a report publication announcement since it contains substantive content about the business update. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release, capital update, or management report.
2022-02-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for Transcenta Holding Limited. It details movements in authorized and issued shares, share options, and confirmations related to securities issued during the month ended 31 January 2022. The document is regulatory in nature, providing updates on share capital and share issuance but does not contain financial statements, management discussion, or detailed financial results. It is a compliance filing related to share capital movements under the Exchange Listing Rules, not an annual or interim financial report, earnings release, or management report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-02-08 English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON PHASE I CLINICAL TRIAL FOR TST001 FOR PRESENTATIONS AT 2022 ASCO GI AND IGCC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Transcenta Holding Limited providing a business update on Phase I clinical trials for their drug candidate TST001. It details presentations at upcoming scientific conferences (ASCO GI and IGCC) and describes the clinical trial progress and scientific data to be presented. There are no financial statements, regulatory filings, voting results, or management changes. The document is an announcement of business progress and clinical trial updates rather than a formal financial or regulatory report. It is not a report publication announcement since it contains substantive information about the clinical trial status and presentations. Therefore, the best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-01-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for Transcenta Holding Limited. It details movements in authorized and issued share capital, share options, and confirmations related to securities issued during the month. The document is regulatory in nature, providing updates on share capital and share issuance but does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, nor an earnings release or investor presentation. It is also not a proxy, voting result, or remuneration report. The document fits the category of a regulatory filing related to share capital movements and confirmations under exchange listing rules. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8612 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or report publication notice.
2022-01-06 English
GRANT OF RESTRICTED SHARE UNITS PURSUANT TO THE PRE-IPO EQUITY INCENTIVE PLAN
Director's Dealing Classification · 95% confidence The document is an announcement regarding the grant of restricted share units (RSUs) to an executive director under a pre-IPO equity incentive plan. It details the number of RSUs granted, the vesting schedule, the market value, and the board's approval. There is no financial data, no report or financial statements, and no mention of a meeting or voting results. The document is a corporate announcement about a share-based remuneration transaction involving a director, which fits the category of Director's Dealing (DIRS) as it reports a personal share-related transaction by a company director. The document length is 5657 characters, which is sufficient for a detailed announcement but does not constitute a full report like an annual or interim report. Therefore, the appropriate classification is DIRS with high confidence.
2022-01-03 English
APPOINTMENT OF CHIEF FINANCIAL OFFICER
Board/Management Information Classification · 100% confidence The document is an announcement from Transcenta Holding Limited regarding the appointment of a new Chief Financial Officer. It includes biographical details of the appointee and is issued by the Board of Directors. There is no financial data, report, or presentation included. The content clearly relates to a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2021-12-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.